Literature DB >> 2842086

[3H]-8-cyclopentyl-1,3-dipropylxanthine binding to A1 adenosine receptors of intact rat ventricular myocytes.

D Martens1, M J Lohse, U Schwabe.   

Abstract

The purpose of the present study was the identification of A1 adenosine receptors in intact rat ventricular myocytes, which are thought to mediate the negative inotropic effects of adenosine. The adenosine receptor antagonist [3H]-8-cyclopentyl-1,3-dipropylxanthine was used as radioligand. Binding of the radioligand to intact myocytes was rapid, reversible, and saturable with a binding capacity of 40,000 binding sites per cell. The dissociation constant of the radioligand was 0.48 nM. The adenosine receptor antagonists 8-cyclopentyl-1,3-dipropylxanthine, "xanthine amine congener," and theophylline were competitive inhibitors with affinities in agreement with results obtained for A1 receptors in other tissues. Competition experiments using the adenosine receptor agonists R-N(6)-phenylisopropyladenosine, 5'-N-ethylcarboxamidoadenosine, and S-N(6)-phenylisopropyladenosine gave monophasic displacement curves with Ki values of 50 nM, 440 nM, and 4,300 nM, which agreed well with the GTP-inducible low affinity state in cardiac membranes. The low affinity for agonists was not due to agonist-induced desensitization, and correlated well with the corresponding IC50 values for the inhibition of cyclic AMP accumulation by isoprenaline. It is suggested that only a low affinity state of A1 receptors can be detected in intact rat myocytes due to the presence of high concentrations of guanine nucleotides in intact cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2842086     DOI: 10.1161/01.res.63.3.613

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  10 in total

1.  Differential effects of adenosine A2a and A2b receptors on cardiac contractility.

Authors:  P Charukeshi Chandrasekera; Victoria J McIntosh; Frank X Cao; Robert D Lasley
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-10-08       Impact factor: 4.733

2.  Characterization of the K(+)-channel-coupled adenosine receptor in guinea pig atria.

Authors:  H Tawfik-Schlieper; K N Klotz; V A Kreye; U Schwabe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-12       Impact factor: 3.000

3.  Thyrotropin regulates adenosine A(1) receptor expression in rat thyroid FRTL-5 cells.

Authors:  M Vainio; B B Fredholm; K Törnquist
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

4.  Adenosine A₂A and A₂B receptors are both required for adenosine A₁ receptor-mediated cardioprotection.

Authors:  Enbo Zhan; Victoria J McIntosh; Robert D Lasley
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-07-08       Impact factor: 4.733

5.  Comparison of A1 adenosine receptors in brain from different species by radioligand binding and photoaffinity labelling.

Authors:  K N Klotz; H Vogt; H Tawfik-Schlieper
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-02       Impact factor: 3.000

6.  Evidence of spare A1-adenosine receptors in guinea pig atrioventricular node.

Authors:  D Dennis; K Jacobson; L Belardinelli
Journal:  Am J Physiol       Date:  1992-03

7.  Characterization of adenosine receptors in intact cultured heart cells.

Authors:  D el-Ani; K A Jacobson; A Shainberg
Journal:  Biochem Pharmacol       Date:  1994-08-17       Impact factor: 5.858

8.  Modulation of basal L-type Ca2+ current by adenosine in ferret isolated right ventricular myocytes.

Authors:  Y Qu; D L Campbell; A R Whorton; H C Strauss
Journal:  J Physiol       Date:  1993-11       Impact factor: 5.182

9.  The binding of 1,3-[3H]-dipropyl-8-cyclopentylxanthine to adenosine A1 receptors in rat smooth muscle preparations.

Authors:  J A Peachey; S M Hourani; I Kitchen
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

10.  Differences in the GTP-regulation of membrane-bound and solubilized A1-adenosine receptors.

Authors:  M Ströher; C Nanoff; W Schütz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-07       Impact factor: 3.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.